Pharmaceuticals Saudi Arabia

Saudi Arabia Shingles Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Saudi Arabia Shingles Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Saudi Arabia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $92.5 Mn Placeholder estimate
Estimate 2025 $100.2 Mn 1.9% of the global market
Projected 2034 $205.3 Mn 105% Adds $105.1 Mn over 9 forecast years
CAGR 2025–2034 8.3% Faster than 33% of 180 Pharmaceuticals markets here
Key players 5
  • Saudi Arabia is 1.94% of the global market.
  • In Middle East, the largest is Saudi Arabia (this report) at $100.2 Mn.
  • Fastest growing: Saudi Arabia (this report) at 8.3% a year.
  • Saudi Arabia ranks 1st of 2 by size in Middle East.

Market size projection

Saudi Arabia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$105.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Shingles Vaccines Market market size by year, Saudi Arabia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $92.5 Mn — —
2025 (base) $100.2 Mn +$7.7 Mn —
2026 (forecast) $108.5 Mn +$8.3 Mn +8.3%
2027 (forecast) $117.5 Mn +$9.0 Mn +17.3%
2028 (forecast) $127.2 Mn +$9.8 Mn +27%
2029 (forecast) $137.8 Mn +$10.6 Mn +37.6%
2030 (forecast) $149.2 Mn +$11.4 Mn +49%
2031 (forecast) $161.6 Mn +$12.4 Mn +61.4%
2032 (forecast) $175.0 Mn +$13.4 Mn +74.7%
2033 (forecast) $189.6 Mn +$14.5 Mn +89.2%
2034 (forecast) $205.3 Mn +$15.7 Mn +105%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $5.15 Bn
  2. North America $2.66 Bn
  3. US $1.98 Bn
  4. Europe $1.00 Bn
  5. APAC $976.7 Mn
  6. China $468.3 Mn
  7. Canada $395.1 Mn
  8. Japan $351.7 Mn
  9. Latin America $261.4 Mn
  10. Middle East $210.1 Mn
  11. Germany $182.6 Mn
  12. Italy $140.2 Mn
  13. Brazil $135.4 Mn
  14. France $120.7 Mn
  15. UK $117.4 Mn
  16. Saudi Arabia (this report) $100.2 Mn
  17. Ecuador $96.8 Mn
  18. India $100.6 Mn
  19. Africa $90.2 Mn
  20. Spain $86.6 Mn
  21. Mexico $70.3 Mn
  22. Australia $66.6 Mn
  23. New Zealand $57.6 Mn
  24. Russia $53.6 Mn
  25. South Africa $30.2 Mn
  26. UAE $25.7 Mn
  27. Egypt $16.3 Mn
  28. Philippines $10.2 Mn
  29. Hong Kong $9.4 Mn
  30. Malaysia $9.1 Mn
  31. Singapore $6.7 Mn
  32. Thailand $6.0 Mn
  33. Kenya $3.1 Mn

Report snapshot

Saudi Arabia Shingles Vaccines Market Analysis at a glance
Market size, 2025$100.2 Mn placeholder estimate
Forecast, 2034$205.3 Mn placeholder estimate
Growth (CAGR), 2025–20348.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, age and end user (see all)
Key playersGSK PLC, Merck & Co., Inc., SK bioscience, Pfizer Inc., Curevo (see all)
Regulator in Saudi ArabiaSFDASource: Saudi Food and Drug Authority. Checked 14 Nov 2026.
Active clinical trials1 in Saudi ArabiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Saudi Arabia Shingles Vaccines Market Analysis Executive Summary

Shingles vaccines prevent herpes zoster, a painful rash caused when the chickenpox virus wakes up again, mostly in older adults.

Key segments of the shingles Vaccines market include type (Recombinant Vaccines and Live Attenuated Vaccines) and age (50-64 Years, 65 Years and Above and Immunocompromised Adults).

Bar chart: Saudi Arabia Shingles Vaccines market size, 2024–2034, placeholder estimates. $92.5 Mn in 2024, $100.2 Mn in 2025 and $205.3 Mn in 2034, 8.3% CAGR.
Saudi Arabia Shingles Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Saudi Arabia Shingles Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the shingles Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the shingles Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the shingles Vaccines market.

Competitive Landscape for Shingles Vaccines Market in Saudi Arabia

The shingles Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Shingles Vaccines Market in Saudi Arabia

Shingles Vaccines in Saudi Arabia: rules, payment and research

The Saudi Food and Drug Authority (SFDA) registers medicines before sale.⁠[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).⁠[2] ClinicalTrials.gov lists 1 study on Shingles Vaccines that is recruiting, active or about to start in Saudi Arabia.⁠[3]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Council of Health Insurance. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for shingles Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Saudi Arabia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Shingles Vaccines right now, from free public sources.

Clinical trials

1 active trial in Saudi Arabia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. GSK PLC 12 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Suzhou Abogen Biosciences Co., Ltd. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Guangzhou Patronus Biotech Co., Ltd. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Sinovac Biotech Co., Ltd 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. CSPC Megalith Biopharmaceutical Co.,Ltd. 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 33 papers since 2021 (worldwide)

  1. Recombinant shingles vaccination and the risk of cardiovascular events. Nature medicine, 2026
  2. Determinants and mitigation strategies of vaccine hesitancy toward routine immunisations recommended for older adults: a systematic review. Age and ageing, 2026
  3. FDA blocks publication of studies showing covid and shingles vaccines to be safe. BMJ (Clinical research ed.), 2026
  4. Vaccine adherence among adult cancer survivors in the United States. Journal of the National Cancer Institute, 2026
  5. A randomized assessment of the impact of 'Those Nerdy Girls' newsletters on adult vaccination outcomes. PloS one, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Shingles Vaccines in context

Saudi Arabia compared

  • Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 9 countries we cover in Middle East.[1]
  • Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). Highest of the 9 countries we cover in Middle East.[2]
  • People aged 65 and over: 3.1% of people (2025). World: 10.4% of people (2025). 6th highest of the 9 countries we cover in Middle East.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Shingles Vaccines market in Saudi Arabia?
Placeholder estimate: about $100.2 Mn in 2025, rising to about $205.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Shingles Vaccines market in Saudi Arabia growing?
Placeholder estimate: about 8.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Shingles Vaccines market report cover?
The report splits the market by type (Recombinant Vaccines, Live Attenuated Vaccines), age (50-64 Years, 65 Years and Above, Immunocompromised Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Shingles Vaccines market?
Key players include GSK PLC, Merck & Co., Inc., SK bioscience, Pfizer Inc. and Curevo.
What is driving the Shingles Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the shingles Vaccines market.
Who regulates Shingles Vaccines in Saudi Arabia?
The Saudi Food and Drug Authority (SFDA) registers medicines before sale. Source: Saudi Food and Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Saudi Arabia?
Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI). Source: Council of Health Insurance. Checked 14 Nov 2026.
How many clinical trials on Shingles Vaccines are running in Saudi Arabia?
1 study is recruiting, active or about to start in Saudi Arabia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 12 Nov 2026.
How much research is published on Shingles Vaccines?
PubMed lists 33 papers on Shingles Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Shingles Vaccines in Saudi Arabia? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Bone and Joint Health: Supplements for an Ageing Population1.71 billion people live with musculoskeletal conditions, including 528 million with osteoarthritis. Evidence… Eye Health Supplements: Screens, Ageing and Vision2.2 billion people have a vision impairment. One supplement formula has strong trial evidence, but only for a… Collagen Supplements: Skin, Joints and Real EvidenceCollagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Saudi Arabia

See all
Same topic, other categories

Related on vaccines and geriatric

See the topic